Stem Cells and Skin Cancer Prevention and Angiogenesis

干细胞和皮肤癌的预防和血管生成

基本信息

  • 批准号:
    9045587
  • 负责人:
  • 金额:
    $ 37.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-03 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Epidermal cancer stem (ECS) cells are important potential targets of dietary cancer prevention agents. We have developed in vitro and in vivo cultivation systems that allow propagation of human ECS cells from squamous cell carcinoma. Using this system, we show that ECS cells display markedly enhanced sensitivity to treatment with dietary cancer prevention agent, sulforaphane (SFN), as compared to non-stem cancer cells. We propose that ECS cell subpopulation of tumor cells is selectively targeted by sulforaphane. We further show that expression of the polycomb group (PcG) stem cell maintenance protein, Ezh2, is markedly elevated in the ECS cell population and that SFN treatment suppresses the level of this regulator. We hypothesize that ECS cells are ultra-sensitive to SFN, compared to non-stem cancer cells, and that SFN reduces Ezh2 protein level and function thereby altering downstream target gene expression to reduce ECS cell survival. We further hypothesize that Ezh2 controls tumor cell production of angiogenic factors that drive tumor vascularization to permit rapid tumor expansion, and that SFN inhibits this. However, we do not have a good understanding of this regulation. First, what is the role of Ezh2 as a mediator of enhanced stem cell sensitivity to SFN and is suppression of Ezh2 protein function required for SFN-dependent suppression of cancer stem cell survival? Second, we do not know if ECS cells will display a similar enhanced SFN sensitivity in vivo and so it will be important to test. Third, we do not know the mechanism whereby Ezh2 and SFN influence tumor cell production of angiogenic agents to drive endothelial cell-dependent tumor vascularization. Our goal is to characterize the sulforaphane anti-stem cell mechanism of action with an ultimate goal of developing sulforaphane as an epidermal stem cell-directed cancer prevention agent.
 描述(由申请人提供):表皮癌干细胞(ECS)是膳食癌症预防剂的重要潜在靶点。我们已经开发了体外和体内培养系统,允许从鳞状细胞癌增殖人ECS细胞。使用这个系统,我们表明,ECS细胞显示出显着增强的敏感性与饮食癌症预防剂,萝卜硫素(SFN)的治疗相比,非干细胞癌细胞。我们提出,肿瘤细胞的ECS细胞亚群被萝卜硫素选择性地靶向。我们进一步表明,表达的polycomb组(PcG)干细胞维持蛋白,Ezh2,是显着升高的ECS细胞群和SFN治疗抑制这种调节剂的水平。我们假设与非干细胞癌细胞相比,ECS细胞对SFN超敏感,并且SFN降低Ezh2蛋白水平和功能,从而改变下游靶基因表达以降低ECS细胞存活。我们进一步假设Ezh2控制肿瘤细胞产生血管生成因子,这些因子驱动肿瘤血管形成以允许肿瘤快速扩张,而SFN抑制了这一点。但是,我们对这项规定并没有很好的理解。首先,Ezh2作为增强干细胞对SFN敏感性的介体的作用是什么?Ezh2蛋白功能的抑制是否是癌症干细胞存活的SFN依赖性抑制所必需的?其次,我们不知道ECS细胞是否会在体内显示出类似的增强的SFN敏感性,因此重要的是, test.第三,我们不知道Ezh2和SFN影响肿瘤细胞产生血管生成剂以驱动内皮细胞依赖性肿瘤血管形成的机制。我们的目标是表征萝卜硫素抗干细胞作用机制,最终目标是开发萝卜硫素作为表皮干细胞导向的癌症预防剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard L. Eckert其他文献

Delivery of growth factor to wounds using a genetically engineered biological bandage.
使用基因工程生物绷带将生长因子输送到伤口。
  • DOI:
    10.1002/jbm.820270911
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. A. Leyen;Daniel J. Smith;J. Bulgrin;Irwin A. Schafer;Richard L. Eckert
  • 通讯作者:
    Richard L. Eckert
2014 Annual Meeting of the Medical Dermatology Society
  • DOI:
    10.1038/jid.2014.168
  • 发表时间:
    2014-07-01
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Tiffany M. Scharadin;Richard L. Eckert
  • 通讯作者:
    Richard L. Eckert
The sequence of the human epidermal 58-kD (#5) type II keratin reveals an absence of 5' upstream sequence conservation between coexpressed epidermal keratins.
人表皮 58-kD 的序列(
  • DOI:
  • 发表时间:
    1988
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Richard L. Eckert;E. Rorke
  • 通讯作者:
    E. Rorke
Transcription factor regulation of epidermal keratinocyte gene expression
  • DOI:
    10.1007/bf00357073
  • 发表时间:
    1996-01-01
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Richard L. Eckert;Jean F. Welter
  • 通讯作者:
    Jean F. Welter

Richard L. Eckert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard L. Eckert', 18)}}的其他基金

A novel sulforaphane cancer preventionmechanism
一种新型萝卜硫素癌症预防机制
  • 批准号:
    10335161
  • 财政年份:
    2018
  • 资助金额:
    $ 37.4万
  • 项目类别:
A novel sulforaphane cancer preventionmechanism
一种新型萝卜硫素癌症预防机制
  • 批准号:
    10088420
  • 财政年份:
    2018
  • 资助金额:
    $ 37.4万
  • 项目类别:
A novel sulforaphane cancer preventionmechanism
一种新型萝卜硫素癌症预防机制
  • 批准号:
    10524235
  • 财政年份:
    2018
  • 资助金额:
    $ 37.4万
  • 项目类别:
A novel sulforaphane cancer preventionmechanism
一种新型萝卜硫素癌症预防机制
  • 批准号:
    9754991
  • 财政年份:
    2018
  • 资助金额:
    $ 37.4万
  • 项目类别:
Stem Cells and Skin Cancer Prevention and Angiogenesis
干细胞和皮肤癌的预防和血管生成
  • 批准号:
    9248258
  • 财政年份:
    2015
  • 资助金额:
    $ 37.4万
  • 项目类别:
Keratoderma- an Exploratory Study
角化病——一项探索性研究
  • 批准号:
    8740156
  • 财政年份:
    2013
  • 资助金额:
    $ 37.4万
  • 项目类别:
Keratoderma- an Exploratory Study
角化病——一项探索性研究
  • 批准号:
    8588676
  • 财政年份:
    2013
  • 资助金额:
    $ 37.4万
  • 项目类别:
Polycomb genes and keratinocyte function
多梳基因和角质形成细胞功能
  • 批准号:
    7847204
  • 财政年份:
    2009
  • 资助金额:
    $ 37.4万
  • 项目类别:
Polycomb genes and keratinocyte function
多梳基因和角质形成细胞功能
  • 批准号:
    7900702
  • 财政年份:
    2009
  • 资助金额:
    $ 37.4万
  • 项目类别:
Bmi-1 and Skin Cancer Prevention
Bmi-1 和皮肤癌预防
  • 批准号:
    8284462
  • 财政年份:
    2008
  • 资助金额:
    $ 37.4万
  • 项目类别:

相似海外基金

How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
  • 批准号:
    22KJ0818
  • 财政年份:
    2023
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10711027
  • 财政年份:
    2021
  • 资助金额:
    $ 37.4万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10297199
  • 财政年份:
    2021
  • 资助金额:
    $ 37.4万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10625314
  • 财政年份:
    2021
  • 资助金额:
    $ 37.4万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10405070
  • 财政年份:
    2021
  • 资助金额:
    $ 37.4万
  • 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
  • 批准号:
    20K06385
  • 财政年份:
    2020
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
  • 批准号:
    17K11866
  • 财政年份:
    2017
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
  • 批准号:
    15K20874
  • 财政年份:
    2015
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
  • 批准号:
    15K15523
  • 财政年份:
    2015
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
  • 批准号:
    26860367
  • 财政年份:
    2014
  • 资助金额:
    $ 37.4万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了